, 8:349 | Cite as

Inhibition of angiogenesis by vitamin D-binding protein: Characterization of anti-endothelial activity of DBP-maf

  • Satyan Kalkunte
  • Laurent BrardEmail author
  • Cornelius O. Granai
  • Narasimha Swamy


Angiogenesis is a complex process involving coordinated steps of endothelial cell activation, proliferation, migration, tube formation and capillary sprouting with participation of intracellular signaling pathways. Regulation of angiogenesis carries tremendous potential for cancer therapy. Our earlier studies showed that vitamin D-binding protein-macrophage activating factor (DBP-maf) acts as a potent anti-angiogenic factor and inhibits tumor growth in vivo. The goal of this investigation was to understand the effect of DBP-maf on human endothelial cell (HEC) and the mechanism of angiogenesis inhibition. DBP-maf inhibited human endothelial cell (HEC) proliferation by inhibiting DNA synthesis ( \(\hbox{IC}_{50}=7.8\pm0.15\) μg/ml). DBP-maf significantly induced S- and G0/G1-phase arrest in HEC in 72 h. DBP-maf potently blocked VEGF-induced migration, tube-formation of HEC in a dose dependent manner. In addition, DBP-maf inhibited growth factor-induced microvessel sprouting in rat aortic ring assay. Moreover, DBP-maf inhibited VEGF signaling by decreasing VEGF-mediated phosphorylation of VEGFR-2 and ERK1/2, a downstream target of VEGF signaling cascade. However, Akt activation was not affected. These studies collectively demonstrate that DBP-maf inhibits angiogenesis by blocking critical steps such as HEC proliferation, migration, tube formation and microvessel sprouting. DBP-maf exerts its effect by inhibiting VEGR-2 and ERK1/2 signaling cascades. Understanding the cellular and molecular mechanisms of anti-endothelial activity of DBP-maf will allow us to develop it as an angiogenesis targeting novel drug for tumor therapy.


angiogenesis DBP-maf endothelial cells ERK1/2 VEGF 



This work was supported by funds from the American Heart Association Scientist Development Grant 0230397N (to Dr. Swamy). We thank NIH COBRE Grant 1-P20RR018728 for providing instrumentation support. We also wish to thank Dr. Sunil Shaw for useful suggestions and discussions.


  1. 1.
    Flamme I, Frolich T, Risau W (1997) Molecular mechanisms of vasculogenesis and embryonic angiogenesis. J Cell Physiol 173:206–10PubMedCrossRefGoogle Scholar
  2. 2.
    Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407: 249–57PubMedCrossRefGoogle Scholar
  3. 3.
    Polverini PJ (2002) Angiogenesis in health and disease: Insights into basic mechanisms and therapeutic opportunities. J Dent Educ 66:962–75PubMedGoogle Scholar
  4. 4.
    Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27– 31PubMedCrossRefGoogle Scholar
  5. 5.
    Polverini PJ (1995) The pathophysiology of angiogenesis. Crit Rev Oral Biol Med 6:230–47PubMedCrossRefGoogle Scholar
  6. 6.
    Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4–7PubMedCrossRefGoogle Scholar
  7. 7.
    Folkman J, Merler E, Abernathy C, Williams G (1971) Isolation of a tumor factor responsible for angiogenesis. J Exp Med 133:275–88PubMedCrossRefGoogle Scholar
  8. 8.
    Hanahan D., and Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353–64PubMedCrossRefGoogle Scholar
  9. 9.
    Bamberger ES, Perrett CW (2002) Angiogenesis in epithelian ovarian cancer. Mol Pathol 55:348–59PubMedCrossRefGoogle Scholar
  10. 10.
    Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z (1999) Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13:9–22PubMedGoogle Scholar
  11. 11.
    Ribatti D, Vacca A, Nico B et al. (2002) Angiogenesis and anti-angiogenesis in neuroblastoma. Eur J Cancer 38:750–7PubMedCrossRefGoogle Scholar
  12. 12.
    O’Reilly MS, Holmgren L, Shing Y et al. (1994) Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315–28PubMedCrossRefGoogle Scholar
  13. 13.
    Folkman J (1989) Successful treatment of an angiogenic disease. N Engl J Med. 320:1211–2PubMedGoogle Scholar
  14. 14.
    Liotta LA, Steeg PS, Stetler-Stevenson WG (1991) Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 64:327–36PubMedCrossRefGoogle Scholar
  15. 15.
    Brem S (1999) Angiogenesis and cancer control: From concept to therapeutic trial. Cancer Control. 6:436–58PubMedGoogle Scholar
  16. 16.
    O’Reilly MS, Boehm T, Shing Y et al. (1997) Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277–85PubMedCrossRefGoogle Scholar
  17. 17.
    Gourley M, Williamson JS (2000) Angiogenesis: New targets for the development of anticancer chemotherapies. Curr Pharm Des 6:417–39PubMedCrossRefGoogle Scholar
  18. 18.
    Ellis LM, Liu W, Ahmad SA et al. (2001) Overview of angiogenesis: Biologic implications for antiangiogenic therapy. Semin Oncol 28:94–104PubMedCrossRefGoogle Scholar
  19. 19.
    O’Reilly MS, Rosenthal R, Sage EH et al. (1993) The suppression of tumor metastases by a primary tumor. Surg Forum 44: 474–6Google Scholar
  20. 20.
    Kisker O, Onizuka S, Becker CM et al. (2003) Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice. Neoplasia 5:32–40PubMedGoogle Scholar
  21. 21.
    Yamamoto N, Kumashiro R (1993) Conversion of vitamin D3 binding protein (group-specific component) to a macrophage activating factor by the stepwise action of beta-galactosidase of B cells and sialidase of T cells. J Immunol 151: 2794 – 802PubMedGoogle Scholar
  22. 22.
    Swamy N, Ghosh S, Schneider GB, Ray R (2001) Baculovirus-expressed vitamin D-binding protein-macrophage activating factor (DBP-maf) activates osteoclasts and binding of 25-hydroxyvitamin D(3) does not influence this activity. J Cell Biochem 81:535–46PubMedCrossRefGoogle Scholar
  23. 23.
    Gomme PT, Bertolini J (2004) Therapeutic potential of vitamin D-binding protein. Trends Biotechnol. 22:340–5PubMedCrossRefGoogle Scholar
  24. 24.
    Gumireddy K, Reddy CD, Swamy N (2003) Mitogen-activated protein kinase pathway mediates DBP-maf-induced apoptosis in RAW 264.7 macrophages. J Cell Biochem 90:87–96PubMedCrossRefGoogle Scholar
  25. 25.
    Malich G, Markovic B, Winder C (1997) The sensitivity and specificity of the MTS tetrazolium assay for detecting the in vitro cytotoxicity of 20 chemicals using human cell lines. Toxicology 124:179–92PubMedCrossRefGoogle Scholar
  26. 26.
    Gratzner HG (1982) Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: A new reagent for detection of DNA replication. Science 218:474–5PubMedCrossRefGoogle Scholar
  27. 27.
    Ormerod MG (ed.). (1990) A Practical Approach in Flow Cytometry. Oxford University Press, New York, pp. 69–81Google Scholar
  28. 28.
    Lee OH, Kim YM, Lee YM et al. (1999) Sphingosine 1-phosphate induces angiogenesis: Its angiogenic action and signaling mechanism in human umbilical vein endothelial cells. Biochem. Biophys Res Commun 264:743–50PubMedCrossRefGoogle Scholar
  29. 29.
    Ashton AW, Yokota R, John G et al. (1999) Inhibition of endothelial cell migration, intercellular communication and vascular tube formation by thromboxane A2, J Biol Chem 274:35562–70PubMedCrossRefGoogle Scholar
  30. 30.
    Nicosia RF, Ottinetti A (1990) Growth of microvessels in serumfree matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro. Lab Invest 63:115–22PubMedGoogle Scholar
  31. 31.
    Murry JC. Angiogenesis Protocols. In Murry JC (ed.), Methods in Molecular Medicine. Vol. 46. Totowa, NJ: Humana Press Scientific and Medical Publishers, 2001; 185–204Google Scholar
  32. 32.
    Voyta JC, Via DP, Butterfield CE, Zetter BR (1984) Identification and isolation of endothelial cells based on their increased uptake of acetylated-low density lipoprotein. J Cell Biol 99:2034–40PubMedCrossRefGoogle Scholar
  33. 33.
    Kanda S, Tomasini-Johanson B, Klint P et al. (1999) Signaling via fibroblast growth factor receptor-1 is dependent on extracellular matrix in capillary endothelial cell differentiation. Exp Cell Res 248:203–13PubMedCrossRefGoogle Scholar
  34. 34.
    Nicosia RF, Ottinetti A (1990) Growth of microvessels in serum-free matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro. Lab Invest 63:115–22PubMedGoogle Scholar
  35. 35.
    Devy L, Blacher S, Grignet-Debrus C et al. (2002) The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J 16:147–54PubMedCrossRefGoogle Scholar
  36. 36.
    Meyer RD, Rahimi N (2003) Comparative structure-function analysis of VEGFR-1 and VEGFR-2: What have we learned from chimeric systems?. Ann NY Acad Sci 995:200–7PubMedGoogle Scholar
  37. 37.
    Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27–31PubMedCrossRefGoogle Scholar
  38. 38.
    Abedi H, Zachary I (1997) Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells. J Biol Chem 272:15442–51PubMedCrossRefGoogle Scholar
  39. 39.
    Gomme PT, Bertolini J (2004) Therapeutic potential of vitamin D-binding protein. Trends Biotechnol. 22:340–5PubMedCrossRefGoogle Scholar
  40. 40.
    Zachary I (2003) VEGF signalling: Integration and multi-tasking in endothelial cell biology. Biochem Soc Trans 117:1–7Google Scholar
  41. 41.
    Cirri L, Donnini S, Morbidelli L et al. (1999) Endostatin: A promising drug for antiangiogenic therapy.Int J Biol Markers 14:263–7PubMedGoogle Scholar
  42. 42.
    Maione TE, Gray GS, Petro J et al. (1990) Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 247: 77–9PubMedCrossRefGoogle Scholar
  43. 43.
    Kusaka M, Sudo K, Matsutani E et al. (1994) Cytostatic inhibition of endothelial-cell growth by angiogenesis inhibitor TNP-470 (AGM-1470). Br J Cancer 69: 212–6PubMedGoogle Scholar
  44. 44.
    Gentilini G, Kirschbaum NE, Augustine JA et al. (1999) Inhibition of human umbilical vein endothelial cell proliferation by the CXC chemokine, platelet factor 4 (PF4), is associated with impaired downregulation of p21(Cip1/WAF1). Blood 93: 25–33PubMedGoogle Scholar
  45. 45.
    Folkman J (2003) Angiogenesis and apoptosis. Semin Cancer Biol 13:159–67PubMedCrossRefGoogle Scholar
  46. 46.
    Bailar JC 3rd, Gornik HL. Cancer undefeated. N Engl J Med 1997;336: 1569–74PubMedCrossRefGoogle Scholar
  47. 47.
    Klohs WD, Hamby JM (1999) Antiangiogenic agents. Curr Opin Biotechnol 10: 544–9PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Satyan Kalkunte
    • 1
  • Laurent Brard
    • 1
  • Cornelius O. Granai
    • 1
  • Narasimha Swamy
    • 1
  1. 1.Department of Pediatrics and Program in Women’s OncologyWomen and Infants’ Hospital, Brown UniversityProvidenceUSA

Personalised recommendations